Experience of using mometasone in seasonal allergic rhinitis patients

Intranasal glucocorticosteroids are the drugs of choice for the basic treatment of moderately severe persistent allergic rhinitis (AR).

The aim: to evaluate the efficacy and safety of mometasone (mometasone fuorate nasal spray dosed 50 mcg/dose) when administered intranasally in adult patients with persistent seasonal AR (SAR).

Material and methods. An open, prospective, single-center, uncontrolled study of the efficacy and safety of intranasal mometasone at a daily dose of 200 mcg was performed. It involved 58 patients (mean age 36.8 ± 11.2 years) with a diagnosis of seasonal persistent AR of moderate severity clinical course. The duration of the study was 14 days. The criterion for assessing the efficacy of therapy was dynamics of AR symptoms in accordance with the total nasal symptom scale (TNSS), visual analogue scale (VAS), assessment of the quality of life using life quality questionnaire for patients suffering from rhinoconjunctivitis (RQLQ), assessment of the overall efficacy of therapy by the patient and the doctor after 14 days of therapy. The safety of the medicine was estimated by recording adverse events.

Results. As a result of treatment, a significant reduction of nasal symptoms according to TNSS scale was registered by 70.8% (p < 0.05). The mean VAS score was 63.9% lower than the baseline value (p < 0.05). The average total score on the RQLQ questionnaire decreased by 78.2% (p < 0.05). The study drug demonstrated high safety and good tolerability.

Conclusion. The results of the study showed that mometasone metered nasal spray has clinically significant efficacy and safety in the treatment of SAR in adult patients.